NS-229

DRUG2 trials

Sponsors

Ns Pharma Inc., NS Pharma, Inc.

Conditions

Churg-Strauss SyndromeEosinophilic Granulomatosis With PolyangiitisEosinophilic granulomatosis with polyangiitis (EGPA)

Phase 2

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Active, not recruitingNCT06046222

NS Pharma, Inc.Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis

Start: 2023-12-20End: 2026-12-01Target: 45Updated: 2026-05-26

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

RecruitingCTIS2023-504245-32-00

Ns Pharma Inc.Eosinophilic granulomatosis with polyangiitis (EGPA)

Start: 2024-06-06Target: 20Updated: 2025-08-14